Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 6/20 | 0.43 |
| ▸ | MTOR | P42345 | 3/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.41 |
| ▸ | FEN1 | P39748 | 3/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16028422 | 0.88 | IDO1 (0.46) | GRM5CDK8ALOX5APFEN1CDK7 | |
| SCHEMBL16028506 | 0.82 | GRM5 (0.45) | GRM5SCN9AFPR2SCN10A | |
| SCHEMBL16028599 | 0.81 | LTA4H (0.43) | CDK8MTORLTA4HPIK3CA | |
| SCHEMBL23900459 | 0.81 | CDK8 (0.50) | CDK8ALOX5APFEN1SCN9ALTA4H | |
| SCHEMBL28460970 | 0.81 | GRM5 (0.50) | GRM5SCN9AFPR2SCN10A | |
| SCHEMBL16029265 | 0.80 | LTA4H (0.40) | CDK8LTA4H | |
| SCHEMBL27312519 | 0.79 | GRM5 (0.46) | GRM5SCN9AFPR2SCN10A | |
| SCHEMBL23888645 | 0.78 | MPO (0.43) | CDK8SCN9ALTA4H | |
| SCHEMBL23900460 | 0.78 | ASIC3 (0.50) | CDK8LTA4H | |
| SCHEMBL30086973 | 0.78 | MPO (0.43) | CDK8SCN9ALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968287-B1 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS LLC (US) | 2020-06-24 | — | — | EP | disclosed |
| US-9382228-B2 | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2016-07-05 | — | — | US | disclosed |
| EP-2968287-A2 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | Deciphera Pharmaceuticals, LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20140275080-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014145028-A2 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275080-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | KIT, CSF1R, CSF3R | GRM5 3755/4885CDK8 147/4885MTOR 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.